Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: Phase III (AXIS) trial Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Imidazoles
  • Indazoles
  • Kidney Neoplasms
  • Niacinamide
  • Phenylurea Compounds

abstract

  • Patient-reported outcomes were comparable for second-line axitinib and sorafenib and were maintained at relatively high levels while on treatment, but worsened at EOT. As duration of treatment was longer with axitinib than sorafenib, time to worsening of symptoms can be delayed longer with axitinib.

publication date

  • April 30, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3668468

Digital Object Identifier (DOI)

  • 10.1038/bjc.2013.145

PubMed ID

  • 23579211

Additional Document Info

start page

  • 1571

end page

  • 8

volume

  • 108

number

  • 8